35.02.03 · health-medicine / infectious-disease

Viral pathogenesis: replication cycle, immune evasion, pandemic dynamics (SIR model)

stub3 tiersLean: nonepending prereqs

Anchor (Master): Kermack, W. O. and McKendrick, A. G. — A contribution to the mathematical theory of epidemics (1927)

Intuition Beginner

Viruses are the ultimate parasites — they cannot reproduce on their own, only by hijacking host cells. A virus is just genetic material (DNA or RNA) wrapped in a protein coat, sometimes enclosed in a lipid envelope stolen from the cell it last infected. Alone, a virus is inert, a piece of biological code waiting for the right host. Inside a compatible cell it springs into action, redirecting the cell's machinery to mass-produce copies of itself. The host cell often dies in the process.

The replication cycle follows a fixed script. The virus attaches to a cell using a surface protein that fits a host receptor like a key in a lock — HIV latches onto CD4, the SARS-CoV-2 spike grabs ACE2, influenza hemagglutinin grips sialic acid. It enters, uncoats, and releases its genome. The host cell is then commandeered to copy the viral genes and build viral proteins. New particles assemble and escape, often by bursting the cell. Each released particle can infect a new cell and repeat the cycle.

Some viruses evade immunity by going latent — hiding dormant inside cells for years. Herpesviruses tuck themselves away in nerve cells and reactivate later as cold sores or shingles; HIV integrates into the host genome and persists silently. Others mutate so fast that the immune system cannot keep up. Influenza constantly changes its surface proteins, which is why flu shots need annual updates.

The SIR model divides a population into three groups: Susceptible, Infected, and Recovered. The key number is R0 — the basic reproduction number — which counts how many people each infected person will infect in a fully vulnerable population. When R0 is greater than 1, the epidemic grows; when it is below 1, it fades. Early COVID-19 had an R0 near 3, so without intervention each case spawned about three more, and cases tripled with every generation.

Herd immunity is the finish line. If enough people are immune — through vaccination or prior infection — the virus cannot find enough susceptible hosts, and transmission collapses. The threshold is 1 minus 1/R0 of the population. For a virus with R0 of 3, roughly two-thirds must be immune. This is why vaccination matters even for those who never catch the disease: their immunity breaks the chain for everyone.

Visual Beginner

Replication stage	What happens	Example
Attachment	Viral surface protein binds a host receptor	SARS-CoV-2 spike binds ACE2
Entry	Genome enters via membrane fusion or endocytosis	Influenza in an endosome
Uncoating	Viral genome is released into the cell	HIV capsid opens in the cytoplasm
Replication	Viral genes and proteins are copied	RNA polymerase, reverse transcriptase
Assembly	New particles are built and packaged	Capsids enclose new genomes
Release	Exit by cell lysis or by budding	Cell bursts, or enveloped virus buds off

Immune-evasion strategy	Mechanism	Example
Latency	Dormant genome hides inside host cells	Herpes simplex, varicella-zoster
Antigenic drift	Point mutations alter surface proteins	Influenza seasonal variants
Antigenic shift	Reassortment of genome segments	Pandemic influenza strains
Immunosuppression	The virus kills immune cells	HIV destroys CD4 T cells

Worked example Beginner

Picture an influenza virus drifting inside a droplet of moisture, inhaled by a passenger on a crowded bus. It lands on the mucus lining the upper airway and meets the epithelial cells beneath. Its surface protein, hemagglutinin, binds to sialic acid residues on the cell surface — the attachment step. The lock fits, and the virus is now anchored to its target.

The cell swallows the virus in a membrane pocket called an endosome. As the endosome acidifies, hemagglutinin changes shape, and the viral envelope fuses with the endosome wall. The viral genome — eight separate segments of single-stranded RNA — spills into the cytoplasm. This is uncoating: the genetic instructions are now loose inside the cell.

The viral RNA travels to the nucleus, where the cell's machinery reads it and begins churning out viral proteins and copies of the genome. Fresh segments and structural proteins self-assemble into new virus particles at the cell surface. The cell, exhausted and damaged, releases thousands of new virions — each one able to infect a neighboring cell.

Within hours the infection has spread from one cell to thousands. The immune system detects the damage, inflammation mounts, and the fever and aches of flu begin. The entire drama — from one landing virion to systemic symptoms — follows from that single molecular handshake between hemagglutinin and sialic acid.

Check your understanding Beginner

Formal definition Intermediate+

Viral pathogenesis is the process by which a virus causes disease in a host: it must attach and enter a permissive cell, replicate its genome and express its proteins, assemble progeny virions, and release them — damaging tissue through direct cell death, immune-mediated inflammation, or disruption of normal cellular function.

Viral structure and the Baltimore classification

A virion consists of a nucleic acid genome packaged within a protein shell, the capsid, which is either icosahedral (geometric, roughly spherical) or helical. Many viruses add an outer envelope, a lipid bilayer derived from host cell membranes and studded with viral glycoproteins (spikes) that mediate receptor recognition and entry. Beneath this morphology lies a deeper classification by genome.

David Baltimore's 1971 scheme sorts viruses into seven groups by genome type and replication strategy: I, double-stranded DNA; II, single-stranded DNA; III, double-stranded RNA; IV, positive-sense single-stranded RNA (+ssRNA, directly translatable as mRNA); V, negative-sense ssRNA (which must first be copied into the positive sense); VI, RNA retroviruses that reverse-transcribe their genome into DNA (e.g., HIV); and VII, DNA viruses that replicate through an RNA intermediate (e.g., hepatitis B virus, a hepadnavirus). The scheme predicts which polymerases a virus must encode or carry, since each genome type faces a distinct replication problem (see 33.06.*, the double helix and the central dogma).

The replication cycle

The cycle has six canonical steps. Attachment is receptor-specific: the HIV gp120 envelope glycoprotein binds CD4 plus a co-receptor (CCR5 or CXCR4) on helper T cells; the SARS-CoV-2 spike binds ACE2 on respiratory epithelium; influenza hemagglutinin binds sialic acid. The distribution of these receptors across tissues and species determines tropism — where a virus can infect.

Entry follows by membrane fusion at the plasma membrane (enveloped viruses such as HIV) or by receptor-mediated endocytosis, after which the endosome's low pH triggers fusion or uncoating (influenza). Uncoating releases the genome into the cytoplasm, partially or fully stripping the capsid.

Replication then follows the Baltimore strategy. DNA viruses generally replicate in the nucleus, using host DNA polymerase or a viral one — poxviruses are the notable exception, carrying their own polymerases and replicating entirely in the cytoplasm. RNA viruses replicate in the cytoplasm using an RNA-dependent RNA polymerase (RdRp) they must encode themselves, because host cells possess none. Retroviruses use reverse transcriptase to copy RNA into DNA, which integrase then inserts into a host chromosome as a permanent provirus — the molecular basis of lifelong HIV infection (see 17.05., RNA processing; 33.06., central dogma).

Assembly packages newly synthesized genomes into capsids, with envelope glycoproteins inserted into a host membrane. Release occurs by cell lysis (non-enveloped viruses such as poliovirus, killing the cell outright) or by budding, in which an enveloped virus acquires its lipid envelope as it extrudes through a host membrane, sometimes without immediate lysis. Each released virion can begin the cycle anew (see 35.02.02, bacterial pathogenesis, for the analogous bacteriophage lytic cycle).

Immune evasion strategies

Viruses escape immunity by four principal strategies. Latency lets herpesviruses maintain dormant episomal DNA in neurons (herpes simplex, varicella-zoster) or B cells (Epstein-Barr), reactivating under stress or immunosuppression as cold sores, shingles, or mononucleosis (see 29.09.*, viral disorders). Antigenic variation takes two forms in influenza: antigenic drift — point mutations in hemagglutinin and neuraminidase accumulating under immune selection, driving the annual vaccine reformulation — and antigenic shift, the reassortment of the eight genome segments when two distinct strains co-infect a single cell, producing novel pandemic strains (1918 H1N1, 1957 H2N2, 1968 H3N2, 2009 H1N1).

Error-prone replication generates diversity within a single patient. HIV's reverse transcriptase lacks proofreading and introduces roughly one mutation per $1 0^{4}$ nucleotides copied per cycle; an infected individual therefore harbors a quasispecies, a cloud of related variants from which immune-escape mutants emerge constantly. Immunosuppression is HIV's signature weapon: by killing CD4 helper T cells it dismantles the coordination of adaptive immunity, opening the door to the opportunistic infections and cancers that define AIDS (see 17.10.*, immunology and T cell biology).

Key result: the SIR model and the epidemic threshold Intermediate+

The Kermack-McKendrick SIR compartmental model (1927) is the foundational quantitative result of epidemiology. It partitions a fixed population of size $N$ into susceptible $S (t)$ , infected $I (t)$ , and recovered (or removed) $R (t)$ , governed by three coupled ordinary differential equations:

\frac{d S}{d t} = - β S I / N

\frac{d I}{d t} = β S I / N - γ I

\frac{d R}{d t} = γ I

Here $β$ is the transmission rate (per susceptible-infected contact per unit time) and $γ$ is the recovery (or removal) rate. The term $β S I / N$ is the force of infection: it grows with both the susceptible pool and the infected pool and vanishes when either is depleted. Recovery transfers infected individuals to $R$ at rate $γ I$ , and $1/ γ$ is the mean infectious period. The model encodes a single positive feedback loop — more infected hosts drive more infections — checked only by the depletion of susceptibles.

R0, herd immunity, and control

The basic reproduction number is $R_{0} = β S_{0} / γ$ , evaluated at the start of an outbreak when the population is almost entirely susceptible ( $S_{0} \approx N$ ). The epidemic threshold follows directly from $d I / d t$ at $t = 0$ : infection grows when $β S_{0} / γ > 1$ , that is when $R_{0} > 1$ , and declines when $R_{0} < 1$ . $R_{0}$ is thus the dimensionless number that decides whether an outbreak ignites or sputters out, and it depends jointly on the pathogen's transmissibility ( $β$ ), its infectious duration ( $1/ γ$ ), and the available pool of susceptible hosts.

The herd immunity threshold is the immune fraction $p_{c} = 1 - 1/ R_{0}$ at which the effective reproduction number $R_{e} = R_{0} (1 - p)$ falls to 1 and transmission can no longer sustain itself. Measles, with $R_{0} \approx 12$ -18, requires roughly 92-94% immunity; polio ( $R_{0} \approx 7$ ) about 85%; seasonal influenza ( $R_{0} \approx 1.3$ -1.8) only 25-45%. Control interventions lower $R_{e}$ by reducing $β$ (distancing, masks, ventilation), increasing $γ$ (treatment that shortens infectiousness), or shrinking $S$ directly through vaccination. A vaccine of efficacy $E$ delivered to a fraction $v$ of the population contributes $E \cdot v$ to the immune pool, so the coverage required is $v \geq p_{c} / E$ .

Limits of the basic model

The basic SIR model assumes homogeneous mixing, no latent period, permanent immunity, and a closed population — assumptions that every real epidemic violates. SEIR models add an Exposed-but-not-yet-infectious compartment for diseases with a latent period (SARS-CoV-1, COVID-19). SIS models, with no durable immunity, suit gonorrhea and the common cold. Age-structured and network models capture heterogeneous contact patterns that drive superspreading (see 37.05., probability and Markov chains; 43., numerical methods for ODEs). Despite these simplifications, the model's central insight holds: an epidemic peaks and reverses once susceptibles are depleted below $N / R_{0}$ , and it halts well before everyone has been infected.

Exercises Intermediate+

Exercise 2 (medium, multiple choice).

Antigenic shift in influenza, which can generate pandemic strains, requires:

A. Gradual accumulation of point mutations in hemagglutinin

B. Reassortment of genome segments when two distinct strains co-infect one cell

C. Reverse transcription of the viral genome into DNA

D. Integration of viral DNA into a host chromosome

Hint

Recall that influenza has a segmented genome, and consider what "shift" implies about the source of the new surface proteins.

Answer

Option B. Antigenic shift is reassortment: when two influenza strains infect the same cell, their eight genome segments can be repackaged into a single progeny virion bearing a novel combination of surface proteins to which the population has little immunity. Option A describes antigenic drift. Reverse transcription (C) and integration (D) are retroviral strategies, not influenza's.

Exercise 4 (hard, short answer).

In the basic SIR model, show why an epidemic self-limits even without any intervention, and derive the final-size relation linking $R_{0}$ to the fraction of the population eventually infected.

Hint

Divide $d S / d t$ by $d R / d t$ to eliminate time, then integrate. Use $S_{0} \approx N$ and $R_{0} = β S_{0} / γ$ .

Answer

The force of infection $β S I / N$ depletes $S$ as the epidemic proceeds. Infection grows while $d I / d t > 0$ , i.e. while $β S / γ > 1$ , or $S > N / R_{0}$ . Once susceptibles fall below $N / R_{0}$ , $d I / d t$ turns negative and the epidemic declines — driven down not by running out of infected hosts but by the depletion of susceptible ones. To get the final size, eliminate time: $d S / d R = (d S / d t) / (d R / d t) = - β S I / N \div (γ I) = - (β / (γ N)) S = - R_{0} S / N$ . Using $R_{0} = β S_{0} / γ \approx β N / γ$ , integrate $d S / S = - (R_{0} / N) d R$ with $S (0) = S_{0}$ , $R (0) = 0$ to obtain $S (t) = S_{0} exp (- R_{0} R (t) / N)$ . Taking $t \to \infty$ where $I \to 0$ and (in a closed population) $S_{\infty} + R_{\infty} = N$ , the attack rate $r = R_{\infty} / N = 1 - S_{\infty} / N$ satisfies $1 - r = exp (- R_{0} r)$ . This transcendental final-size equation fixes the total fraction ever infected as a function of $R_{0}$ alone: for $R_{0} = 3$ , roughly 94% are eventually infected, an insight with no dependence on intervention timing within the basic model.

Advanced results Master

Zoonotic spillover and One Health

Most emerging human infections are zoonotic, and David Quammen's Spillover (2012) frames the search for "the next big one" as an ecological detective story. Roughly 60% of newly described infectious diseases, and the great majority of recent high-consequence outbreaks, cross into humans from animal reservoirs — most often bats, whose flight-driven metabolism and immune tolerance make them enduring hosts for viruses they shed without illness. Hendra moves from bats to horses to humans; Nipah from bats to pigs to humans; SARS-CoV-1 from bats through civets; MERS from bats through camels; Ebola from bats directly. Highly pathogenic avian influenza strains (H5N1, H7N9) circulate in poultry and sporadically infect humans with high case fatality, retaining pandemic potential should they acquire sustained human-to-human transmissibility (see 35.02.02, bacterial pathogenesis and bioterrorism).

The One Health framework recognizes that human, animal, and environmental health are coupled: deforestation, agricultural intensification, and climate-driven range shifts bring wildlife, livestock, and people into novel contact, and land-use change is among the strongest predictors of spillover (see 27.07., climate change; 19.10., community ecology). Jared Diamond's analysis in Guns, Germs, and Steel traces how millennia of domestication assembled the crowd diseases that later devastated immunologically naive populations during the Columbian Exchange (see 31.04.*, human evolution and domestication; 32.14.02, the Columbian Exchange). The same logic now operates on a faster timescale, compressed by global travel and dense supply chains.

Viral oncogenesis

About 10-15% of human cancers worldwide have a viral etiology, and the mechanisms by which viruses drive malignancy were central to discovering the genes that govern cell division. Human papillomavirus (HPV) expresses two oncogenes, E6 and E7, that bind and inactivate the tumor suppressors p53 and retinoblastoma protein (Rb), abolishing the checkpoints that would normally trigger apoptosis or arrest in a damaged cell; persistent infection with high-risk HPV types causes nearly all cervical cancer (see 35.03.03, cancer biology and tumor suppressors; 17.06.06, epigenetics and viral oncogenes). Hepatitis B and C viruses drive hepatocellular carcinoma through a mix of chronic inflammation, regenerative turnover, and — for HBV — viral integration.

Epstein-Barr virus (EBV) is implicated in Burkitt lymphoma and nasopharyngeal carcinoma; HTLV-1 in adult T-cell leukemia/lymphoma; Merkel cell polyomavirus in a subset of aggressive skin carcinomas. These associations reframed cancer as a disease of dysregulated growth control, in which a viral gene product subverts the cell's own signaling (see 33.06., viral genetics and oncogenes; 20.05., philosophy of biology and cancer as an evolutionary process). The HBV and HPV vaccines were the first to prevent cancer by preventing the infection that causes it — a public-health landmark (see 35.06.03).

Antiviral drugs and curative therapy

Antiviral design exploits differences between viral and host enzymes. Acyclovir is a prodrug activated only inside infected cells, where the viral thymidine kinase phosphorylates it into a chain-terminating nucleotide analog that blocks herpesvirus DNA polymerase — a strategy that maximizes selectivity. HAART (highly active antiretroviral therapy) combines reverse transcriptase inhibitors, protease inhibitors, and integrase inhibitors to suppress HIV replication from multiple angles simultaneously, blocking the emergence of resistant mutants and converting HIV from a death sentence into a manageable chronic infection (see 29.10.03, biological treatments and pharmacotherapy).

The breakthrough against hepatitis C was the arrival of direct-acting antivirals such as sofosbuvir, which target viral NS5B polymerase and achieve cure rates above 95% in 8-12 weeks — the first genuinely curative antiviral regimen for a chronic infection (see 35.07., pharmacology and drug design). Broad-spectrum agents followed: remdesivir, an RdRp inhibitor developed for Ebola and repurposed for COVID-19; and Paxlovid (nirmatrelvir, a 3CL protease inhibitor, boosted by ritonavir), which cuts COVID-19 hospitalization when given early. These molecules are products of rational, structure-based design (see 33.04., the chemistry revolution; 35.07.03, drug classes).

Vaccine platforms: from Pasteur to mRNA

Two centuries of vaccinology have produced a palette of platforms, each trading immunogenicity against safety and manufacturability. Live attenuated vaccines (Sabin oral polio, measles-mumps-rubella) elicit strong, durable immunity but risk reversion and cannot be given to the immunocompromised. Inactivated vaccines (Salk polio, rabies) are safer but weaker. Subunit vaccines present defined antigens — recombinant HBV surface antigen, HPV virus-like particles — and are safe but often need adjuvants. Viral-vector vaccines (adenovirus-based, for Ebola and Johnson & Johnson COVID-19) deliver antigen genes inside a harmless virus.

The mRNA platform, realized in the Pfizer-BioNTech and Moderna COVID-19 vaccines, delivers antigen-coding mRNA inside a lipid nanoparticle, turning the recipient's own cells into antigen factories. Its speed — from genome sequence to clinical candidate in weeks — rested on Katalin Karikó and Drew Weissman's discovery that nucleoside modification suppresses innate immune recognition of exogenous RNA, a result that made mRNA therapeutically viable (see 35.06.03, vaccine science and the mRNA platform; 33.06.*, the double helix and Karikó-Weissman). The platform now underpins candidate vaccines for influenza, HIV, RSV, and several cancers — but its benefits were distributed inequitably, with low-income countries waiting months for doses (see 20.02.06, AI ethics and vaccine distribution; 30.07.03, global inequality).

Mathematical epidemiology beyond SIR

Roy Anderson and Robert May's Infectious Diseases of Humans (1991) generalized the SIR framework into a theory of population dynamics for pathogens, treating $R_{0}$ as a unifying parameter across directly transmitted, vector-borne, and macroparasitic diseases. The Ross-Macdonald model, foundational for malaria, partitions transmission between humans and mosquitoes and showed that reducing mosquito longevity below a threshold can interrupt transmission even without eliminating the vector — the quantitative basis of bed-net and indoor-residual-spraying campaigns.

Network epidemiology replaces homogeneous mixing with explicit contact graphs and explains superspreading: in a heterogeneous network, a minority of individuals generate the majority of secondary transmissions (the "20/80" rule), so targeted interventions on high-degree nodes can be far more efficient than population-wide measures (see 37., probability and networks). Stochastic branching processes describe early-stage outbreaks, where the fate of an epidemic is not certain extinction or growth but a probability of stochastic fade-out that depends on $R_{0}$ and the number of initial cases. Spatial metapopulation models couple subpopulations through air-travel networks, capturing how a local outbreak seeds global spread within days (see 27.04., atmospheric circulation and global transport). Phylodynamics inverts the relationship: the shape of a pathogen's phylogenetic tree, inferred by molecular-clock dating of sequenced genomes, records the history of its effective population size and transmission rate, letting genomic surveillance reconstruct epidemic dynamics in real time (see 19.07.*, phylogenetics; 28.05.03, exoplanet demographics and analogous inference).

Connections Master

Molecular biology and the central dogma

Virology and molecular biology are coextensive: the central dogma was mapped using viruses. The discovery of reverse transcriptase in retroviruses overturned the dogma's original one-way formulation (RNA cannot specify DNA), and Baltimore's classification is essentially a taxonomy of how each virus navigates the flow from nucleic acid to protein. RNA splicing, cap-dependent translation, and RNA interference were all first characterized in viral systems (see 33.06., the double helix and central dogma; 17.05., molecular biology and RNA processing).

Immunology and the CD4 axis

HIV's pathogenesis is a case study in how a virus can defeat an immune system by targeting the system's own coordinator. The depletion of CD4 helper T cells dismantles the signaling that activates cytotoxic T cells, B cells, and macrophages, producing the broad immune failure that defines AIDS. The immune-evasion arms race — between viral quasispecies generation and the adaptive immune repertoire — structures both fields, and broadly neutralizing antibodies against HIV are among the most studied molecules in immunology (see 17.10.*, immunology and T cell biology; 29.09.03, anxiety and trauma, HIV).

Cancer biology and oncogenes

The viral oncogenes of HPV, EBV, and HTLV-1 were the route by which cell biology identified the host genes — p53, Rb, the myc family — that govern cell-cycle control. Tumor virology and cancer genetics are thus two faces of one program: viruses revealed the regulatory circuits whose disruption defines malignancy, and the vaccines against HBV and HPV are among the few interventions that prevent cancer at its root cause (see 35.03.03, cancer biology and tumor suppressors).

Pharmacology and rational drug design

Every major antiviral class — nucleoside analogs, protease inhibitors, integrase inhibitors, polymerase inhibitors — is a product of structure-based design against a viral enzyme. The HCV cure, achieved by direct-acting antivirals within a decade of the virus's discovery, is the cleanest demonstration that knowing a pathogen's protein structures can yield a curative drug. The same logic now guides broad-spectrum design against conserved viral targets (see 35.07., pharmacology; 33.04., the chemistry revolution and rational drug design).

Evolution, ecology, and One Health

Viral emergence is an ecological process: pathogens cross species boundaries at rates set by land use, biodiversity loss, and climate, and within-host evolution generates the diversity on which immune escape and drug resistance act. Quammen's spillover framing and the One Health agenda unite virology with conservation biology and climate science, treating pandemic prevention as a problem of managing the interfaces between wildlife, livestock, and people (see 27.07., climate change; 19.10., community ecology; 19.02.*, population genetics).

Public health, ethics, and global equity

Pandemics expose the asymmetry between where diseases emerge and where they are treated. Vaccine nationalism, intellectual-property disputes over mRNA technology, and the 10/90 gap in research funding all show that the biological SIR model is inseparable from its social container. Paul Farmer's work on HIV in Haiti and Rwanda reframed access to treatment as a question of structural violence, not merely logistics (see 35.06., public health; 20.02., bioethics; 30.07.03, global inequality; 31.06.02, medical anthropology).

History, society, and the politics of contagion

Epidemics have always been political events. The 1918 influenza was shaped by wartime censorship; HIV/AIDS by stigma and activist mobilization; COVID-19 by misinformation, polarized institutions, and contested expertise. The media ecosystem through which a population learns about an outbreak is now part of the transmission dynamics themselves, so that understanding a pandemic requires understanding the communication channels that carry fear, denial, and compliance (see 32.20.02, WWI; 30.07., social movements; 36., media literacy and disinformation; 29.01.03, statistical reasoning and vaccine-efficacy data).

Historical and philosophical context Master

Kermack, McKendrick, and the mathematical theory of epidemics (1927)

William Ogilvy Kermack and Anderson Gray McKendrick's 1927 paper, A contribution to the mathematical theory of epidemics, introduced the compartmental model that still bears their names. Working at the laboratory of the Royal College of Physicians in Edinburgh, they sought to explain a striking empirical regularity: epidemics often terminate while many susceptible individuals remain uninfected. Their explanation was mathematical rather than biological — the rate of new infections depends on the product of susceptible and infected populations, so as susceptibles are consumed the epidemic starves itself of fuel long before the population is exhausted. This was the first rigorous statement of the threshold theorem and of $R_{0}$ as the quantity governing outbreak ignition.

The modern synthesis generalizes Kermack and McKendrick's formulation to age structure, networks, and stochasticity, but the core insight is unchanged: epidemics are threshold phenomena, and the threshold is set by a dimensionless combination of biological and social parameters. Anderson and May's Infectious Diseases of Humans (1991) consolidated half a century of extensions into the canonical text, embedding $R_{0}$ as the central parameter of infectious-disease ecology (see 37.05., probability and Markov chains; 43., numerical methods for ODE solving).

Baltimore and classification by strategy (1971)

David Baltimore's 1971 essay, Expression of animal virus genomes, proposed that viruses be classified not by their morphology or disease but by the strategy they use to express their genomes — by the path from their nucleic acid to messenger RNA. The resulting seven groups unified a disparate bestiary under a single logic, and they predicted, for each group, which exotic polymerases the virus would have to bring along. Reverse transcriptase, discovered by Temin and Baltimore in 1970, was the founding anomaly that made the scheme necessary: here was a virus that flowed against the central dogma, copying RNA into DNA.

Baltimore's classification is more than taxonomy; it is a statement that a virus is defined by its information-flow strategy. It survives because it maps cleanly onto molecular mechanism and onto the targets of antiviral drugs, which are almost always the polymerases and proteases each group requires (see 33.06.*, the double helix and the central dogma).

Zoonotic spillover: Quammen's "the next big one"

David Quammen's Spillover (2012) reframed pandemic risk for a general audience by tracing each major emerging infection back to its ecological origin — the moment a virus crossed from its reservoir host into a new species. Quammen's central claim, drawn from the work of virologists and ecologists, is that spillover is not a freak event but the predictable consequence of how humans now occupy the planet: encroaching on forests, intensifying livestock production, and moving people and animals across continents in hours. "The next big one," he warned, was less a question of whether than of when, and of which virus.

The COVID-19 pandemic vindicated the framing with grim precision. The deeper philosophical point is that pandemics are not external disasters visited upon a passive humanity but the return signal of a species' own ecological footprint — a view that places virology inside conservation biology and climate science rather than beside them (see 27.07., climate change; 19.10., community ecology).

HIV/AIDS: stigma, activism, and structural violence

The HIV/AIDS pandemic is inseparable from the social conditions that shaped both its spread and its response. In its first decades the disease was concentrated among gay men, injecting drug users, and sex workers — groups already marginal in most societies — and the slowness of the early response reflected that marginalization as much as it reflected scientific uncertainty. The activist movement, most visibly ACT UP, forced an acceleration of drug approval and a rethinking of the relationship between patients, researchers, and regulators (see 30.07.*, social movements and patient activism).

Paul Farmer's ethnographic and clinical work in Haiti and Rwanda argued that the course of an epidemic is set by structural violence — the political and economic arrangements that distribute risk and care unevenly. His insistence that treatment could be delivered in resource-poor settings, against the skepticism of the time, reshaped global HIV policy and helped build the infrastructure through which antiretroviral therapy now reaches tens of millions (see 31.06.02, medical anthropology and structural violence).

COVID-19 and the mRNA revolution

The COVID-19 pandemic, declared by the World Health Organization in March 2020, was simultaneously a failure of preparedness and a triumph of platform science. The SARS-CoV-2 genome was sequenced and released within weeks of the first cases, and candidate vaccines entered clinical trials before the pandemic had reached much of the world. The mRNA vaccines, built on Katalin Karikó and Drew Weissman's decades of uncelebrated work on nucleoside-modified RNA, were authorized within a year of pathogen identification — a speed that would have been inconceivable a generation earlier.

The deeper lesson is technological and social at once. The mRNA platform's modularity means the same manufacturing process can be redirected against a new pathogen by swapping the coding sequence, collapsing vaccine development into design rather than discovery. Whether the political will that compressed the COVID-19 timeline survives into peacetime — for tuberculosis, malaria, and the next pandemic — remains an open question, and one that turns on equity as much as on science (see 33.06.*, Karikó-Weissman; 35.06.03, vaccine science).

Pandemic cycles and the limits of institutional memory

A striking feature of pandemic history is how regularly each generation relearns the same lessons. The 1832 cholera pandemic was blamed on miasma and moral failing, delaying the sanitation response; the 1918 influenza was masked by wartime censorship; the early HIV response was slowed by stigma; COVID-19 by denial, polarized institutions, and an infodemic of misinformation. Each episode left a residue of public-health infrastructure — quarantine conventions, sanitation systems, surveillance networks — and each was followed by a slow erosion of the funding and trust that infrastructure required.

The philosophical question is why institutions struggle to retain what science has already established. Part of the answer is that pandemic countermeasures require collective action during the calm between storms, when the threat is abstract and the costs are immediate. The SIR model is, in this sense, a tool for remembering: it makes the threshold visible in advance, so that the cost of complacency can be computed rather than merely lamented after the fact (see 36.*, media literacy; 30.02.03, moral panic).

Bibliography Master

Murray, P. R., Rosenthal, K. S. & Pfaller, M. A. (2020). Medical Microbiology (9th ed.). Elsevier. Ch. 20-30, Virology.
Knipe, D. M. & Howley, P. M. (Eds.) (2021). Fields Virology (7th ed., 2 vols.). Wolters Kluwer.
Kermack, W. O. & McKendrick, A. G. (1927). "A contribution to the mathematical theory of epidemics." Proceedings of the Royal Society of London A, 115(772), 700-721.
Anderson, R. M. & May, R. M. (1991). Infectious Diseases of Humans: Dynamics and Control. Oxford University Press.
Baltimore, D. (1971). "Expression of animal virus genomes." Bacteriological Reviews, 35(3), 235-241.
Temin, H. M. & Mizutani, S. (1970). "RNA-dependent DNA polymerase in virions of Rous sarcoma virus." Nature, 226, 1211-1213.
Quammen, D. (2012). Spillover: Animal Infections and the Next Human Pandemic. W. W. Norton.
Karikó, K., Buckstein, M., Ni, H. & Weissman, D. (2005). "Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA." Immunity, 23(2), 165-175.
Farmer, P. (1999). Infections and Inequalities: The Modern Plagues. University of California Press.
Grenfell, B. T. et al. (2004). "Unifying the epidemiological and evolutionary dynamics of pathogens." Science, 303(5656), 327-332.
Galvani, A. P. & May, R. M. (2005). "Epidemiology: dimensions of superspreading." Nature, 438, 293-295.

Prerequisites

35.02.01 pending

Used in

35.02.04

Tier anchors

beginner: Murray, P. R. et al. — Medical Microbiology, 9th ed. (2020)
intermediate: Knipe, D. M. and Howley, P. M. — Fields Virology, 7th ed. (2021)
master: Kermack, W. O. and McKendrick, A. G. — A contribution to the mathematical theory of epidemics (1927)

References

Murray, P. R., Rosenthal, K. S. & Pfaller, M. A. — Medical Microbiology, 9th ed. (Elsevier, 2020) · Ch. 20-30 Virology
Knipe, D. M. & Howley, P. M. (eds.) — Fields Virology, 7th ed., 2 vols. (Wolters Kluwer, 2021) · Comprehensive virology
Anderson, R. M. and May, R. M. — Infectious Diseases of Humans: Dynamics and Control (Oxford, 1991) · SIR model and R0
Quammen, D. — Spillover: Animal Infections and the Next Human Pandemic (Norton, 2012) · Zoonotic emergence

Estimated time

beginner: 15m
intermediate: 30m
master: 45m